

## Supplementary material

### Experimental procedures for CircRNA detection

#### 1. Sample preprocessing

The peripheral blood (about 5 ml) collected from pregnant women using EDTA anticoagulant tubes was immediately stored at 4°C and processed within 2 h. These samples were centrifuged twice at 3000 rpm at 4°C and the supernatant (i.e. plasma) was retained and stored at -80°C until testing.

#### 2. Total RNA

According to the manufacturer's instructions, the total RNAs of these samples were extracted using Trizol reagent (Invitrogen, Gaithersburg, MD, United States), and purified using a NucleoSpin RNA Clean-up kit (Macherey-Nagel, Germany). Then, a NanoDrop 2000 spectrophotometer (Nano-Drop, USA) was used to quantify purified total RNA and an Agilent 2100 Bioanalyzer (Agilent Technologies, USA) was used to verify the RNA integrity.

#### 3. RNase R treatment

For each sample, 5 µg of RNA, 2 µl of RNase R 10X Reaction Buffer, and 0.5 µl of RNase R were mixed in the 20 µl reaction system, followed by instantaneous centrifugation. The digestion reaction was performed at 37°C for 30 min. Then, RNA was purified using a NucleoSpin RNA Clean-up kit (Macherey-Nagel, Germany).

#### 4. cDNA synthesis

##### 4.1 First strand cDNA

Total RNA 100-500 ng was added to the 0.2 ml nuclease-free microcentrifuge tube and then the appropriate volume of spike-in controls was added (Agilent Technologies, USA) according to the table below.

Starting amount of RNA		Serial dilutions			Spike-in mix volume to be used in each labeling reaction [µl]
Total RNA [ng]	Max. volume of RNA [µl]	First	Second	Third	
200	8.3	1 : 20	1 : 25	1 : 10	2
300	7.3	1 : 20	1 : 25	1 : 10	3
400	6.3	1 : 20	1 : 25	1 : 10	4
500	5.3	1 : 20	1 : 25	1 : 10	5

The reverse transcription Master Mix was prepared by gently mixing 4 µl of First Strand Buffer Mix and 1 µl of First Strand Enzyme Mix. It was instantaneously centrifuged and placed in an ice bath. The Master Mix (5 µl) was added to the previously prepared 0.2 ml nuclease-free microcentrifuge tube containing total RNA and spike-in controls.

The solution was gently mixed, instantaneously centrifuged, and then reacted at 42°C for 2 h. After the reaction, it was instantaneously centrifuged and ice-bathed in sequence, and then the subsequent steps were performed immediately.

#### 4.2 Second strand cDNA

The Second Strand Master Mix was prepared by gently mixing 13 µl of Nuclease-free Water, 5 µl of Second Strand Buffer Mix, and 2 µl of Second Strand Enzyme Mix. It was instantaneously centrifuged and placed in an ice bath. Then, 20 µl of Second Strand Master Mix was added to the reacted system generated in step 4.1.

The solution was gently mixed and reacted at 16°C for 1 h, then at 65°C for 10 min.

#### 5. cRNA synthesis

The In vitro Transcription Master Mix was prepared by gently mixing 4 µl of Nuclease-free Water, 20 µl of T7 Buffer Mix, and 6 µl of T7 Enzyme Mix. It was instantaneously centrifuged and added to the reacted system generated in step 4.2.

The solution was gently mixed and reacted at 40°C for 8–14 h. Following this, the cRNA was purified using a NucleoSpin RNA Clean-up kit (Macherey-Nagel, Germany).

#### 6. cRNA reverse transcription

The purified cRNA (5 µg/7.5 µl) and Random Primer (4 µl) were added to a 0.2 ml nuclease-free centrifuge tube, mixed gently, and reacted at 65°C for 5 min, followed by an ice bath for 5 min.

The cRNA reverse transcription Master Mix was prepared by gently mixing 5 µl of 4X Script II Buffer, 2 µl of 0.1 M DTT, and 1.5 µl of CbcScript II. It was instantaneously centrifuged and transferred to the solution generated in the last step.

The mixture was gently mixed, instantaneously centrifuged, and then reacted at 25°C for 10 min and 37°C for 1.5 h.

After the reaction, Terminate Solution (5 µl) was added to the system and gently mixed. The mixture was reacted at 65°C for 10 min and stood at room temperature for 5 min. Neutralize Solution (1 µl) was added to this mixture and gently mixed.

The cDNA was purified using NucleoSpin Extract II (Macherey-Nagel, Germany) following the

manufacturer's instructions. The purified cDNA was quantified using the spectrophotometer ( $1\text{OD}_{260} = 40 \mu\text{g}/\mu\text{l}$ ).

### 7. Fluorescence labeling

The volume of the purified cDNA was concentrated to 14  $\mu\text{l}$ . The Random Primer 4  $\mu\text{l}$  was added to it, mixed well, instantaneously centrifuged, denatured at 95°C for 3 min, and ice-bathed for 5 min. Then, 5  $\mu\text{l}$  of 5X Klenow Buffer, 1  $\mu\text{l}$  of Cy5-dCTP (or Cy3-dCTP), and 1.2  $\mu\text{l}$  of Klenow Fragmen were added to it. The mixture was gently mixed, instantaneously centrifuged, and then reacted at 37°C for 1.5 h and 70°C for 5 min.

The labeled production of this step was purified using NucleoSpin Extract II (Macherey-Nagel, Germany) following the manufacturer's instructions and then quantified using the spectrophotometer ( $1\text{OD}_{260} = 50 \mu\text{g}/\mu\text{l}$ ).

### 8. Microarray hybridization

The hybridization mixture was prepared according to the following table:

Reagent	Standard volume
2X GEx Hyb Buffer (HI-RPM)	55.0 $\mu\text{l}$
Formamide	27.5 $\mu\text{l}$
Sample	27.5 $\mu\text{l}$
Total volume prepared	110 $\mu\text{l}$

The hybridization mixture was added to the circRNA microarray (CapitalBio Corporation, Beijing, China), and hybridization was performed in the hybridization oven (Agilent Technologies, USA) at 20 rpm for 16 h.

### 9. Microarray washing and scanning

After hybridization, the circRNA microarray was washed in wash solution I containing 0.2% SDS and 2×SSC at 42°C for 5 min and wash solution II containing 0.2×SSC at room temperature for 5 min.

The washed microarray was scanned by a G2565CA Microarray Scanner (Agilent Technologies, USA) to obtain hybridization images.

### 10. Data extraction and analysis

Agilent Feature Extraction (v10.7) software was used to analyze the hybridization images and extract the data, which were then normalized using Agilent GeneSpring software.

All the processes of microarray analysis were conducted by the Bioassay Laboratory of Capital-Bio Corporation (Beijing, China).

**Supplementary Table S1.** Clinical characteristics of pregnant women

Patients ID	Age	BMI	Primigravida	Primiparity	Delivery modes	Delivery [gestational weeks]	Sampling 1 [gestational weeks]	Interval from sampling 1 to delivery [h]	Sampling 2 [hours after delivery]
L281	27	28.2	Yes	Yes	Vaginal	38.3	38.1	16	5
L284	28	32.4	No	No	Caesarean	39.9	39.7	26	44
L302	31	33.3	No	No	Vaginal	30.6	30.3	51	15
L317	28	23.7	No	Yes	Vaginal	29.6	29.1	108	30
L325	27	25.2	Yes	Yes	Vaginal	34.9	34.4	69	12
L328	27	29.0	Yes	Yes	Caesarean	34.3	34.1	16	42
L332	38	24.4	No	No	Caesarean	32.4	32.3	29	40

**Supplementary Table SII.** The expression of Y-circRNA in circulation of male and female neonate

Sample	SRR376	SRR377	SRR378	SRR380	SRR381	SRR395	SRR396	SRR397	SRR398	SRR400	SRR405	SRR406	SRR406	SRR387	SRR388	SRR389	SRR390	SRR391	SRR392	SRR393	SRR394	SRR401	SRR402	SRR403	SRR404
Sex	Female	Male																							
chrY:14510475 14518736	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:14652909 14655340	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:14802255 14826722	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:14813939 14821476	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:14821321 14834120	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:14821321 14851563	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15021271 15024974	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15024875 15025765	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15024875 15026561	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15362897 15438230	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15372158 15438230	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15390121 15448215	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15409587 15417992	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15409587 15438230	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15409587 15448215	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15414808 15470401	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15418036 15425648	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15418066 15433592	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:154354 15438230	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:154354 15447680	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:154354 15448215	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:154354 15508852	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15441739 15469849	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15447443 15448215	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15447443 15472408	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15466666 15478273	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15466883 15467898	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15466883 15478273	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15466883 15481229	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15469757 15526673	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15470344 15471102	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15481136 15515768	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15511818 15512566	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15511818 15515768	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:15515767 15582109	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:21094629 21095361	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:21094629 21144882	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:21205049 21206581	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:21738591 21752658	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:21749056 21749393	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
chrY:21751407 21761717	0	0</td																							

